Clinical trial · Observational
Long-term Effects of Methadone for Cancer Pain
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The methadone is an useful opioid for the cancer pain treatment, mostly used in second or last line during the opioid rotation. The Methadone had an anti-MNDA effect, and clinicians agree that the methadone could have an effect in neuropathic cancer pain. During a previous study the investigators find that the pain was still improving after the week 2, but they had only a small number of patients still included at this stage and they cannot conclude. The investigators decide to follow up systematically all the patients undergoing a methadone treatment for cancer pain, at day 28, to study the hypothesis about the long-term pain improvement.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Pain | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Difference between EVA pain score at Day 28 and Day 0
- timeFrame
- pain score measure at Day 0 and Day 28
- description
- long-term effects of methadone for cancer pain
Secondary outcomes (4)
- measure
- Change in score of neuropathic pain intensity NPSI
- timeFrame
- Day 0 and Day 28
- measure
- Change in depression and anxiety score HADS
- timeFrame
- Day 0 and Day 28
- measure
- Change in quality of life score QOL C30
- timeFrame
- Day 0 and Day 28
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with t methadone for cancer pain in opioid rotation * Able to fill the questionnaire * Performance status (PS) from 0 to 2 Exclusion Criteria: * Patients PS 3 * Unable to sign the informed consent
References
Publications (0)
Data not yet available